drugset / Trial / NCT04320238

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

NCT04320238 ↗

Phase 3 Unknown 2944 enrolled Shanghai Jiao Tong University School of Medicine
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.

Timeline

Start
2020-01-21
Primary completion
2020-05
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymosin alpha 1 Peptide — Subcutaneous
Subject recombinant human interferon Alpha-1b Protein / enzyme biologic — Intranasal

Indications